Michael B Boffa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7760750/publications.pdf Version: 2024-02-01



MICHAEL R ROEE

#	Article	IF	CITATIONS
1	A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor. Journal of Biological Chemistry, 1998, 273, 27176-27181.	3.4	329
2	Thrombin, Thrombomodulin and TAFI in the Molecular Link Between Coagulation and Fibrinolysis. Thrombosis and Haemostasis, 1997, 78, 386-391.	3.4	223
3	Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. Circulation, 2019, 139, 1472-1482.	1.6	196
4	Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?. Journal of Lipid Research, 2016, 57, 745-757.	4.2	181
5	Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor. Journal of Biological Chemistry, 2015, 290, 11649-11662.	3.4	176
6	Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). Journal of Lipid Research, 2013, 54, 2815-2830.	4.2	174
7	Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties. Journal of Biological Chemistry, 1998, 273, 2127-2135.	3.4	167
8	Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nature Reviews Cardiology, 2019, 16, 305-318.	13.7	158
9	Two Naturally Occurring Variants of TAFI (Thr-325 and Ile-325) Differ Substantially with Respect to Thermal Stability and Antifibrinolytic Activity of the Enzyme. Journal of Biological Chemistry, 2002, 277, 1021-1030.	3.4	148
10	Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clinical Biochemistry, 2004, 37, 333-343.	1.9	134
11	Subclinical Vitamin K Deficiency in Hemodialysis Patients. American Journal of Kidney Diseases, 2007, 49, 432-439.	1.9	122
12	A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood, 2001, 98, 1992-1993.	1.4	112
13	Roles of Thermal Instability and Proteolytic Cleavage in Regulation of Activated Thrombin-activable Fibrinolysis Inhibitor. Journal of Biological Chemistry, 2000, 275, 12868-12878.	3.4	99
14	Inhibition of Plasminogen Activation by Lipoprotein(a). Journal of Biological Chemistry, 2003, 278, 23260-23269.	3.4	99
15	Lipoprotein(a). Current Opinion in Lipidology, 2012, 23, 133-140.	2.7	99
16	Lipoprotein(a): A Unique Risk Factor for Cardiovascular Disease. Clinics in Laboratory Medicine, 2006, 26, 751-772.	1.4	86
17	Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). Journal of Lipid Research, 2015, 56, 2273-2285.	4.2	85
18	Characterization of the Gene Encoding Human TAFI (Thrombin-Activable Fibrinolysis Inhibitor; Plasma) Tj ETQq0	0 0 rgBT /	Overlock 10 T

#	Article	IF	CITATIONS
19	Curiouser and curiouser: Recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clinical Biochemistry, 2007, 40, 431-442.	1.9	84
20	The renaissance of lipoprotein(a): Brave new world for preventive cardiology?. Progress in Lipid Research, 2017, 68, 57-82.	11.6	63
21	The Apolipoprotein(a) Component of Lipoprotein(a) Stimulates Actin Stress Fiber Formation and Loss of Cell-Cell Contact in Cultured Endothelial Cells. Journal of Biological Chemistry, 2004, 279, 6526-6533.	3.4	55
22	Association of a single nucleotide polymorphism in <i>CPB2</i> encoding the thrombinâ€activable fibrinolysis inhibitor (TAFI) with blood pressure. Clinical Genetics, 2001, 60, 345-349.	2.0	52
23	Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). Journal of Lipid Research, 2014, 55, 625-634.	4.2	52
24	The Solution Phase Interaction between Apolipoprotein(a) and Plasminogen Inhibits the Binding of Plasminogen to a Plasmin-Modified Fibrinogen Surface. Biochemistry, 1997, 36, 10353-10363.	2.5	50
25	Acute Phase Mediators Modulate Thrombin-activable Fibrinolysis Inhibitor (TAFI) Gene Expression in HepG2 Cells. Journal of Biological Chemistry, 2003, 278, 9250-9257.	3.4	46
26	Apolipoprotein(a) inhibits the conversion of Gluâ€plasminogen to Lysâ€plasminogen: a novel mechanism for lipoprotein(a)â€mediated inhibition of plasminogen activation. Journal of Thrombosis and Haemostasis, 2008, 6, 2113-2120.	3.8	46
27	Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis. Blood, 2008, 111, 183-189.	1.4	42
28	Development of an LC-MS/MS Proposed Candidate Reference Method for the Standardization of Analytical Methods to Measure Lipoprotein(a). Clinical Chemistry, 2021, 67, 490-499.	3.2	40
29	Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9. PLoS ONE, 2017, 12, e0180869.	2.5	40
30	New Frontiers in Lp(a)-Targeted Therapies. Trends in Pharmacological Sciences, 2019, 40, 212-225.	8.7	39
31	Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. Journal of Lipid Research, 2019, 60, 2082-2089.	4.2	35
32	Secretion and antifibrinolytic function of thrombinâ€activatable fibrinolysis inhibitor from human platelets. Journal of Thrombosis and Haemostasis, 2010, 8, 2523-2529.	3.8	34
33	Update on Lipoprotein(a) as a Cardiovascular Risk Factor and Mediator. Current Atherosclerosis Reports, 2013, 15, 360.	4.8	32
34	Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology. Atherosclerosis, 2022, 349, 92-100.	0.8	31
35	Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor. Journal of Thrombosis and Haemostasis, 2004, 2, 1969-1979.	3.8	30
36	Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal. Journal of Clinical Lipidology, 2018, 12, 1358-1366.	1.5	30

#	Article	IF	CITATIONS
37	Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis. Atherosclerosis, 2022, 349, 72-81.	0.8	30
38	Stimulation of Vascular Smooth Muscle Cell Proliferation and Migration by Apolipoprotein(a) Is Dependent on Inhibition of Transforming Growth Factor-Î ² Activation and on the Presence of Kringle IV Type 9. Journal of Biological Chemistry, 2004, 279, 55187-55195.	3.4	27
39	Lipoprotein(a). Endocrinology and Metabolism Clinics of North America, 2014, 43, 949-962.	3.2	27
40	Apolipoprotein(a) stimulates nuclear translocation of β-catenin: a novel pathogenic mechanism for lipoprotein(a). Molecular Biology of the Cell, 2013, 24, 210-221.	2.1	26
41	Apolipoprotein(a) Inhibits In Vitro Tube Formation in Endothelial Cells: Identification of Roles for Kringle V and the Plasminogen Activation System. PLoS ONE, 2013, 8, e52287.	2.5	23
42	A Role for CCAAT/Enhancer-binding Protein in Hepatic Expression of Thrombin-activable Fibrinolysis Inhibitor. Journal of Biological Chemistry, 2002, 277, 25329-25336.	3.4	22
43	Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis. BMC Cancer, 2016, 16, 328.	2.6	21
44	Lipoprotein(a) in clinical practice: New perspectives from basic and translational science. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 33-54.	6.1	20
45	IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages. Current Problems in Cancer, 2018, 42, 215-230.	2.0	18
46	Modulation of Fibrin Cofactor Activity in Plasminogen Activation. Annals of the New York Academy of Sciences, 2001, 936, 247-260.	3.8	17
47	Apo(a) and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 289-304.	2.4	17
48	Lipoprotein(a) as a therapeutic target in cardiovascular disease. Expert Opinion on Therapeutic Targets, 2014, 18, 747-757.	3.4	16
49	Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells. Thrombosis and Haemostasis, 2011, 105, 999-1009.	3.4	15
50	Interaction of Autotaxin With Lipoprotein(a) in Patients With Calcific Aortic Valve Stenosis. JACC Basic To Translational Science, 2020, 5, 888-897.	4.1	15
51	Baboon Lipoprotein(a) Binds Very Weakly to Lysineâ^'Agarose and Fibrin Despite the Presence of a Strong Lysine-Binding Site in Apolipoprotein(a) Kringle IV Type 10. Biochemistry, 2005, 44, 555-564.	2.5	14
52	Lipoprotein Proteomics and Aortic Valve Transcriptomics Identify Biological Pathways Linking Lipoprotein(a) Levels to Aortic Stenosis. Metabolites, 2021, 11, 459.	2.9	14
53	Pro-inflammatory cytokines reduce human TAFI expression via tristetraprolin-mediated mRNA destabilisation and decreased binding of HuR. Thrombosis and Haemostasis, 2015, 114, 337-349.	3.4	13
54	Lipoprotein(a): Expanding our knowledge of aortic valve narrowing. Trends in Cardiovascular Medicine, 2021, 31, 305-311.	4.9	13

#	Article	IF	CITATIONS
55	Molecular analysis of the human thrombin-activatable fibrinolysis inhibitor gene promoter. British Journal of Haematology, 2007, 138, 231-244.	2.5	12
56	Functional analysis of mutant variants of thrombin-activatable fibrinolysis inhibitor resistant to activation by thrombin or plasmin. Journal of Thrombosis and Haemostasis, 2009, 7, 665-672.	3.8	12
57	Pathophysiology and Risk of Atrial Fibrillation Detected after Ischemic Stroke (PARADISE): A Translational, Integrated, and Transdisciplinary Approach. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 606-619.	1.6	12
58	Understanding the ins and outs of lipoprotein (a) metabolism. Current Opinion in Lipidology, 2022, 33, 185-192.	2.7	12
59	Screening for and Management of Elevated Lp(a). Current Cardiology Reports, 2013, 15, 417.	2.9	11
60	The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?. Current Opinion in Lipidology, 2018, 29, 259-267.	2.7	11
61	A Comparative Analysis of the Lipoprotein(a) and Low-Density Lipoprotein Proteomic Profiles Combining Mass Spectrometry and Mendelian Randomization. CJC Open, 2021, 3, 450-459.	1.5	11
62	Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone. Blood Coagulation and Fibrinolysis, 2013, 24, 393-404.	1.0	10
63	Lipoprotein(a): lodestar for future clinical trials. Lancet, The, 2018, 392, 1281-1282.	13.7	10
64	Identification of a thrombomodulin interaction site on thrombinâ€activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin. Journal of Thrombosis and Haemostasis, 2016, 14, 772-783.	3.8	9
65	Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease. Current Atherosclerosis Reports, 2016, 18, 69.	4.8	9
66	A role for apolipoprotein(a) in protection of the low-density lipoprotein component of lipoprotein(a) from copper-mediated oxidation. Archives of Biochemistry and Biophysics, 2003, 412, 186-195.	3.0	8
67	Apolipoprotein(a) inhibits the conversion of Clu-plasminogen to Lys-plasminogen on the surface of vascular endothelial and smooth muscle cells. Thrombosis Research, 2018, 169, 1-7.	1.7	8
68	Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a). Journal of Lipid Research, 2020, 61, 1263-1270.	4.2	8
69	Regulation of the mouse gene encoding TAFI by TNFα: Role of NFκB binding site. Cytokine, 2012, 57, 389-397.	3.2	7
70	The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity. Thrombosis and Haemostasis, 2013, 109, 1033-1044.	3.4	7
71	Simultaneous R _{2[*]} and quantitative susceptibility mapping measurement enables differentiation of thrombus hematocrit and age: an in vitro study at 3 T. Journal of NeuroInterventional Surgery, 2019, 11, 1155-1161.	3.3	7
72	Therapeutic Lowering of Lipoprotein(a). Circulation Genomic and Precision Medicine, 2018, 11, e002052.	3.6	6

#	Article	IF	CITATIONS
73	Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins αMβ2 and αVβ3. Atherosclerosis, 2018, 275, 11-21.	0.8	6
74	Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease. Current Opinion in Lipidology, 2019, 30, 428-437.	2.7	6
75	Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a). Journal of Lipid Research, 2022, 63, 100216.	4.2	4
76	Identification of tristetraprolin as a factor that modulates the stability of the TAFI transcript through binding to the 3′-untranslated region. Journal of Thrombosis and Haemostasis, 2012, 10, 887-894.	3.8	3
77	Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment. Clinical and Experimental Metastasis, 2017, 34, 155-169.	3.3	3
78	Lipoprotein(a) as an Emerging Risk Factor for Atherothrombosis. , 2007, , 241-266.		3
79	TAFI and wound healing: closing a knowledge gap. Journal of Thrombosis and Haemostasis, 2003, 1, 2075-2077.	3.8	2
80	Genetics to the Rescue. Journal of the American College of Cardiology, 2021, 78, 450-452.	2.8	2
81	Is resistance futile? The role of activated thrombin-activatable fibrinolysis inhibitor resistance in bleeding in factor XI deficiency. Journal of Thrombosis and Haemostasis, 2016, 14, 1600-1602.	3.8	1
82	Lipoprotein(a). , 2021, , 547-581.		0
83	Regulation of Human Thrombin-Activable Fibrinolysis Inhibitor Gene Expression in Megakaryocyte-Like (Dami) and Monocyte/Macrphage- Like (THP-1) Cell Lines. Blood, 2008, 112, 3078-3078.	1.4	0
84	Regulation of the Gene Encoding Human Thrombin-Activable Fibrinolysis Inhibitor by Female Sex Steroids. Blood, 2008, 112, 3077-3077.	1.4	0
85	Exon Skipping and Alternative Splicing of CPB2 mRNA in Multiple Cell Types Results in Variants of TAFI That Are Inactive and Not Secretable. Blood, 2011, 118, 1189-1189.	1.4	0
86	Apolipoprotein(a)-Dependent Inhibition of Pericellular Plasminogen Activation Is Mediated by Specific Cellular Receptors. Blood, 2011, 118, 2236-2236.	1.4	0
87	Lipoprotein (a): Principles from Bench to Bedside. Contemporary Cardiology, 2021, , 363-381.	0.1	0